Theriva Biologics, Inc.
TOVX
$1.42
$0.00780.55%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 18.92% | -134.02% | -63.54% | -15.34% | 14.90% |
| Total Depreciation and Amortization | -30.77% | 3.13% | 18.75% | 21.88% | 56.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 115.64% | 289.88% | 1,102.19% | 1,800.00% | -180.23% |
| Change in Net Operating Assets | -209.55% | -88.36% | 17.70% | 99.83% | 152.33% |
| Cash from Operations | 28.28% | -32.51% | 11.31% | 12.99% | -21.85% |
| Capital Expenditure | 100.00% | 100.00% | 88.89% | -- | 38.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 100.00% | 88.89% | -- | 38.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -235.00% | -- | -- |
| Issuance of Common Stock | -88.71% | 371,500.00% | -14.66% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 49.37% |
| Cash from Financing | 100.48% | 371,500.00% | -16.99% | -- | 55.69% |
| Foreign Exchange rate Adjustments | -261.84% | 254.55% | 119.05% | -8.57% | 46.15% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 39.75% | 94.18% | 8.75% | 13.82% | 8.25% |